Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Long-Term Debt Issuances
Ratios

Candel Therapeutics (CADL) Accumulated Depreciation & Amortization (2020 - 2023)

Candel Therapeutics' Accumulated Depreciation & Amortization history spans 4 years, with the latest figure at $200000.0 for Q2 2023.

  • For Q2 2023, Accumulated Depreciation & Amortization changed 0.0% year-over-year to $200000.0; the TTM value through Jun 2023 reached $200000.0, changed 0.0%, while the annual FY2022 figure was $800000.0, 300.0% up from the prior year.
  • Accumulated Depreciation & Amortization for Q2 2023 was $200000.0 at Candel Therapeutics, roughly flat from $200000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $800000.0 in Q4 2022 and bottomed at $26000.0 in Q1 2021.
  • The 4-year median for Accumulated Depreciation & Amortization is $200000.0 (2021), against an average of $179153.8.
  • The largest annual shift saw Accumulated Depreciation & Amortization crashed 36.47% in 2021 before it soared 669.23% in 2022.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $91000.0 in 2020, then soared by 119.78% to $200000.0 in 2021, then soared by 300.0% to $800000.0 in 2022, then crashed by 75.0% to $200000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Accumulated Depreciation & Amortization are $200000.0 (Q2 2023), $200000.0 (Q1 2023), and $800000.0 (Q4 2022).